Glioblastoma (GBM, WHO grade IV) accounts for 50% of all the intracranial tumors and 70% of the primary malignant brain tumors. Although GBM often occurs in late adulthood (70% at a mean age of 53 years), up to 8.8% occur during childhood. Absence of specific symptoms is the predominant reason for which tumors are often detected at advanced stages, leading to poor prognosis with a mean survival of 1 year for GBM (18).
█ INTRODuCTIONA ny tumor that arises from the glial or supportive tissue of the brain or the spinal cord is called "glioma". One of the types of glioma is astrocytoma. Astrocytomas arise from astrocytes, the star-shaped cells, and are graded to describe their degree of abnormality. The most common grading system uses a scale of I to IV (15,16,18).AIm: Glioblastoma (GBM) is one of the lethal central nervous system tumors. One of the widely used chemical agents for the treatment of glioblastoma is temozolomide. It is an orally administered, deoxyribonucleic acid (DNA) alkylating agent. DNA alkylation triggers the death of tumor cells. However, some tumor cells are able to repair this type of DNA damage and thus lower the therapeutic effect of temozolomide. Laboratory and clinical studies indicate that temozolomide's anticancer effects might be strengthened when combined with other chemotherapeutic agents like etoposide or antioxidant agents like ascorbic acid. In this study, we aimed to evaluate the cytotoxic and oxidative stress effects of ascorbic acid (1000 µM), temozolomide (100 µM) and etoposide (25 µM) agents alone and in dual and triple combinations in a glioblastoma U87 MG cell culture.
mATERIAl and mEThODS:The cytotoxic and oxidative stress effects were investigated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and liquid chromatography tandem-mass spectrometry (LC-MS/MS) analysis methods.
RESulTS:Cytotoxicity tests showed that etoposide, temozolomide, "etoposide+ascorbic acid", "temozolomide+ascorbic acid", "temozolomide+etoposide" and "temozolomide+etoposide+ascorbic acid" combinations have anti-proliferative effects. The maximum anti-proliferation response was observed in the "temozolomide+etoposide+ascorbic acid"-added group. Similarly LC-MS/MS analyses showed that minimum oxidative DNA damage occurred in the "temozolomide+etoposide+ascorbic acid"-added group.CONCluSION: Ascorbic acid decreases the cytotoxic and genotoxic effect of etoposide and etoposide-temozolomide combination but it has no meaningful effect on temozolomide's toxicity.